Selpercatinib (Retsevmo®) as monotherapy for the treatment of adults and adolescents 12 years and older with advanced RET mutant medullary thyroid cancer (MTC). Update March 2023

Rothschedl, E. and Wolf, S. (2022): Selpercatinib (Retsevmo®) as monotherapy for the treatment of adults and adolescents 12 years and older with advanced RET mutant medullary thyroid cancer (MTC). Update March 2023. Fact Sheet Nr. 108.

[thumbnail of Fact Sheet Nr.108_Update.pdf]

Preview

PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader
102kB

Item Type:	Horizon Scanning of Medicines
Subjects:	QV Pharmacology, toxicology, pharmacy > QV 60-370 Pharmacology QZ Pathology > QZ 200-380 Neoplasms.Cysts WB Practice of medicine > WB 300-962 Therapeutics WK Endocrine system > WK 200-300 Thyroid gland. Parathyroid gland
Language:	English
Series Name:	Fact Sheet Nr. 108
Deposited on:	25 Aug 2022 14:43
Last Modified:	10 Jul 2025 11:35

Repository Staff Only: item control page